Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on August 31, 2015, with the earliest event reported on that date. The filing details significant corporate governance changes, specifically the appointment of a new Chief Operating Officer and the election of a new Director.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes and Personnel Appointments
Appointment of Chief Operating Officer
- Individual: Katharine Lindemann joined as Chief Operating Officer on August 31, 2015.
- Compensation: Annual base salary of $345,000 with a target annual bonus of 40% of base salary.
- Equity: Granted a stock option to purchase 150,000 shares of Common Stock at the closing price on the grant date.
- Vesting Schedule: 25% vests on the first anniversary; the remaining 75% vests monthly over the subsequent three years.
- Severance: Entitled to nine months of salary continuation if terminated without Cause or resigns for Good Reason.
- Change in Control: 100% acceleration of unvested equity awards if terminated without Cause or resigns for Good Reason within a specific window surrounding a Change in Control.
Election of Director
- Individual: Robert Perez was elected to the Board of Directors on September 2, 2015.
- Board Size: The Board size was increased to eight members.
- Term: Designated as a Class II member serving until the 2017 annual meeting.
- Compensation: Granted a non-statutory stock option for 20,000 shares. Eligible for annual cash retainer fees and an annual stock option grant of 10,000 shares.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook statements, or specific risk factors beyond standard employment agreement terms. The primary focus is on the execution of the Executive Employment Agreement and the Director Compensation Policy.
Investor Verification Checklist
- Verify the full text of the Executive Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Confirm the exact grant date and exercise price for Katharine Lindemann's 150,000 stock options.
- Review the press releases (Exhibits 99.1 and 99.2) for additional context on the strategic rationale for these appointments.
- Check subsequent filings for the actual vesting commencement dates and any adjustments to the Board size.